Taken together, these results suggested that the combination of PD-1/PD-L1 antibodies and AKT/mTOR inhibitor might be a promising and novel therapeutic approach for DLBCL in the future. The gene discussed is MTOR; the disease is diffuse large B-cell lymphoma.